Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy fornon-small-cell lung cancer
Élisabeth Quoix, B Lebeau, Alain Depierre et al. · Annals of Oncology · 2003
Cited by 41 works. doi:10.1093/annonc/mdh005
Authors
- Élisabeth Quoix
- B Lebeau
- Alain Depierre
- A Ducoloné
- Denis Moro‐Sibilot
- Bernard J. Milleron
- Jean-Luc Breton
- É. Lemarié
- Jean-Louis Pujol
- J.-M. Bréchot
- Gérard Zalcman
- Didier Debieuvre
- F. Vaylet
- Alain Vergnenégre
- P. Clouet
References
- Reporting results of cancer treatment
- Cancer: Principles and Practice of Oncology.
- Cancer incidence, mortality and prevalence worldwide
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- Cancer—Principles & Practice of Oncology
- GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide, Version 1.0
- Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.